New precision approach could revolutionize osteoporosis care
NCT ID NCT05151484
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a personalized treatment for age-related osteoporosis using the drug teriparatide. Researchers aim to match treatment to each patient's bone turnover rate using simple blood tests, avoiding the need for painful bone biopsies. The trial involves 60 adults aged 45 and older with osteoporosis who have not taken bone drugs before.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Teriparatide (a bone-building drug given as daily injections)
- What this could lead to
- If successful, this could lead to a non-invasive way to tailor osteoporosis treatment to each patient, potentially reducing fractures and hospitalizations.
- What could go wrong
- This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The treatment requires daily injections and carries risks like calcium imbalances.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Kentucky
Lexington, Kentucky, 40536, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.